Drug intelligence / Profile preview

HXSS026

Development stage: Preclinical
Lead developer: Huaxia Shengsheng Pharmaceutical
Modality: Small Molecules

Overview

HXSS026 is a small molecule neuroprotective agent currently in preclinical development by Huaxia Sangsheng Pharmaceutical (华夏生生药业). Developed under a research system led by scientists from the Peking University School of Pharmacy, the compound is intended for the treatment of various neurological diseases. As a neuroprotective agent, it is designed to preserve neuronal integrity and function, although its specific molecular target has not been disclosed. It represents one of the novel drug candidates in the company's pipeline focusing on unmet clinical needs in the central nervous system space.

Beyond the preview

Go deeper on HXSS026.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HXSS026.

Explore the full profile